Skip to main content
European Commission logo print header

Nano-assisted digitalizing of cancer phenotyping for immunotherapy

Descripción del proyecto

Decisión fundamentada sobre la inmunoterapia

La inmunoterapia constituye una estrategia muy prometedora que activa el sistema inmunitario de una persona para combatir el cáncer y genera inmunidad antineoplásica. Sin embargo, la práctica clínica ha demostrado que la inmunoterapia puede provocar reacciones autoinmunitarias, lo cual implica la necesidad de una planificación cuidadosa. El equipo del proyecto ImmunoChip, financiado por el Consejo Europeo de Investigación, pretende desarrollar una plataforma capaz de predecir la idoneidad de una persona para recibir la inmunoterapia. El dispositivo de ImmunoChip combinará la microfluídica y una red nanosensorial para estudiar diversos aspectos del cáncer individual y su microentorno. Junto con la información sobre los componentes del sistema inmunitario, la plataforma ayudará a los médicos a tomar una decisión fundamentada sobre el tipo de inmunoterapia adecuado para cada paciente.

Objetivo

Every day cancer takes about 30000 lives worldwide, despite multiple treatments developed in the last 50 years. True revolution in the therapy is demonstrated by the immunooncology relying on multiple routes to activate the immune system, using e.g. Chimeric Antigen Receptors, checkpoints inhibitors. Although demonstrating success in the treatment of e.g. lymphoma, the percentage of patients responding to the immunotherapy is less than 30%. Even more, the activation of immune system does not happen at no cost, leading to severe auto-immune reactions, sometimes with lethal consequences. Therefore, the main question of clinicians is: how to efficiently predict the response/no-response of the patient to the immunotherapy? At present, there is no predictive technological platform combining both, highly sensitive analysis of the cancer immunity and the planning of the strategy for potential therapy.
I consider cancer as a smart self-adapting machine that plays its own set of rules: it generates and quenches the biochemical signals; initiates the iterative loops and builds up feedback controls to create an immune suppressive environment. My idea is to digitalize these mechanisms. ‘ImmunoChip’ will develop a device combining microfluidics with the specific nanosensory network to study elements of the cancer-immunity cycle to bring a new dimension in the field of preclinical immunotherapeutic cancer phenotyping. The information about the immunosuppressive activity of the cancer microenvironment, immune checkpoints, T cells, efficiency of the immunotherapy, will be collected into respective data patterns. The developed ‘ImmunoChip’ platform will help to answer the questions: can the patient be treated with the immunotherapy? How does the tumor protect itself? Which immunotherapy to use? I am sure that improved decision-making in immunotherapy will lead to a transformative treatment results for more patients and will help to save more lives.

æ

Coordinador

HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF EV
Aportación neta de la UEn
€ 1 993 875,00
Dirección
Bautzner landstrasse 400
01328 Dresden
Alemania

Ver en el mapa

Región
Sachsen Dresden Dresden, Kreisfreie Stadt
Tipo de actividad
Research Organisations
Enlaces
Otras fuentes de financiación
€ 0,00